J Cancer 2021; 12(10):2960-2967. doi:10.7150/jca.55936 This issue Cite

Research Paper

Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors

Na Liu*, Aimin Jiang*, Xiaoqiang Zheng, Xiao Fu, Haoran Zheng, Huan Gao, Jingjing Wang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao

Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, No.277 Yanta West Road, Xi'an, Shaanxi 710061, People's Republic of China.
*These authors contributed equally to this work.

Citation:
Liu N, Jiang A, Zheng X, Fu X, Zheng H, Gao H, Wang J, Liang X, Tian T, Ruan Z, Yao Y. Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors. J Cancer 2021; 12(10):2960-2967. doi:10.7150/jca.55936. https://www.jcancer.org/v12p2960.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: The prognostic nutritional index (PNI) is related to the prognosis of multiple malignancies. This study investigated whether the PNI has prognostic value in advanced non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD-1) inhibitors.

Methods: We retrospectively analyzed advanced NSCLC patients treated with PD-1 inhibitors from July 2018 to December 2019. Pretreatment PNI was calculated by peripheral lymphocyte count and serum albumin level, and the cut-off value was determined. Subsequently, we investigated the relationship between PNI and early progression, and evaluated its prognostic role on survival outcomes. Ultimately, based on the results of survival analysis, a nomogram was established.

Results: A total of 123 patients were included. Of these, 24 (19.5%) patients had experienced early progression. Multivariate logistic analysis indicated that low PNI (odds ratio, 3.709, 95% confidence interval [CI], 1.354-10.161; P = 0.011) was closely correlated with early progression. Moreover, multivariate Cox regression analysis confirmed that low PNI was an independent risk factor for progression-free survival (hazard ratio [HR], 2.698, 95% CI, 1.752-4.153; P < 0.001) and overall survival (HR, 7.222, 95% CI, 4.081-12.781; P < 0.001), respectively. The prediction accuracy of nomogram based on PNI is moderate.

Conclusion: PNI was an independent predictor of early progression and survival outcomes in advanced NSCLC patients treated with PD-1 inhibitors.

Keywords: non-small cell lung cancer, prognosis nutritional index, PD-1 inhibitors, prognosis, nomogram


Citation styles

APA
Liu, N., Jiang, A., Zheng, X., Fu, X., Zheng, H., Gao, H., Wang, J., Liang, X., Tian, T., Ruan, Z., Yao, Y. (2021). Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors. Journal of Cancer, 12(10), 2960-2967. https://doi.org/10.7150/jca.55936.

ACS
Liu, N.; Jiang, A.; Zheng, X.; Fu, X.; Zheng, H.; Gao, H.; Wang, J.; Liang, X.; Tian, T.; Ruan, Z.; Yao, Y. Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors. J. Cancer 2021, 12 (10), 2960-2967. DOI: 10.7150/jca.55936.

NLM
Liu N, Jiang A, Zheng X, Fu X, Zheng H, Gao H, Wang J, Liang X, Tian T, Ruan Z, Yao Y. Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors. J Cancer 2021; 12(10):2960-2967. doi:10.7150/jca.55936. https://www.jcancer.org/v12p2960.htm

CSE
Liu N, Jiang A, Zheng X, Fu X, Zheng H, Gao H, Wang J, Liang X, Tian T, Ruan Z, Yao Y. 2021. Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors. J Cancer. 12(10):2960-2967.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image